retatrutide type 2 diabetes trial results 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Retatrutide as a Novel Treatment

RGNEF4 aids in Ca2+ release via IP3 as well as the Diacylglycerol (DAG) pathway by activating Phospholipase C

For optimal results, it's recommended to take two capsules daily with food, maintaining consistent use for at least 3-6 months

Mitochondrial / Longevity Mitocondrial / Longevidad Cardiolipin-targeting mitochondrial peptide for deep cellular repair and altitude recovery

Even after reaching a target weight, many patients continue semaglutide often at a smaller dose to support chronic weight management and keep the weight off

The mechanism behind Retatrutide is what sets it apart

Who Should Be Cautious With GLP-1 Medications